Anti-MAPK 1/2 Antibody

32160702

NA.41

Mitogen-activated protein kinase 3 (EC 2.7.11.24; UniProt P21708; also known as ERK-1, ERT2, Extracellular signal-regulated kinase 1, Insulin-stimulated MAP2 kinase, MAP kinase 3, MAP kinase isoform p44, MAPK 3, Microtubule-associated protein 2 kinase, MNK1, p44-ERK1, p44-MAPK) is encoded by the Mapk3 (also known as Erk1, Prkm3) gene (Gene ID 50689) in rat species. ERK1 (a.k.a. MAPK 3) and ERK2 (a.k.a. MAPK 1 or MAPK 2) are related serine/threonine kinases of the Ras-Raf-MEK-ERK signaling pathway. ERK1/2 are activated by MEK1/2-catalyzed phosphorylation at their conserved Thr-Glu-Tyr (TEY) dual phosphorylation motif, first at the Tyr residue (human/rat ERK1 Tyr204/Tyr203, human/rat ERK2 Tyr187/Tyr183) and then at the Thr residue (human/rat ERK1 Thr202/Thr201, human/rat ERK2 Thr185/Thr181). ERK1/2 are proline-directed kinases that preferentially catalyze the phosphorylation of Pro-Xxx-Ser/Thr-Pro sequence motif in hundreds of cytoplasmic and nuclear substrates, including transcription factors such as Ets, Elk, and c-Fos. Besides this primary structure requirement, many ERK1/2 substrates possess a D-docking site and/or an F-docking site. A variety of scaffold proteins, including KSR1/2, IQGAP1, MP1, and β-Arrestin1/2, also participate in the regulation of ERK1/2 MAP kinase cascade. Ras-Raf-MEK-ERK signaling activity is upregulated in about one-third of all human cancers, and targeted inhibition against components of this signaling pathway represents a popular anticancer strategy.

This antibody recognizes MAPK 3/MAPK 1 (ERK1/ERK2) C-terminal sequence.

Epitope: C-terminal
KLH-conjugated linear peptide corresponding to the C-terminal sequence of rat MAPK 3 (ERK-1).

Research Sub Category
MAP Kinases
Detect MAPK 3/MAPK 1 (ERK1/ERK2) using this Anti-MAPK 1/2 Antibody validated for use in Immunocytochemistry, Immunoprecipitation, and Western Blotting.
Western Blotting Analysis: 0.5 µg/mL from a representative lot detected MAPK 3/MAPK 1 (ERK1/ERK2) in BALB/3T3, A431, and L6 cell lysates.



Western Blotting (SNAP ID) Analysis: 1-2 µg/mL from a representative lot detected MAPK 3/MAPK 1 (ERK1/ERK2) in BALB/3T3, A431, and L6 cell lysates.



Immunocytochemistry Analysis: A 1:500 dilution from a representative lot detected MAPK 3/MAPK 1 (ERK1/ERK2) in NIH/3T3, A431, HeLa, and C2C12 cells.
Research Category
Signaling

Evaluated by Western Blotting in A431 cell lysate.



Western Blotting Analysis: 0.5 µg/mL of this antibody detected MAPK 3/MAPK 1 (ERK1/ERK2) in 10 µg of A431 cell lysate.

Replaces: 06-182

Protein A purified.
Purified rabbit polyclonal in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.
Format: Purified

Control
A431 cell lysate

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

rabbit

100

purified antibody

primary antibodies

polyclonal

human, rat, mouse

canine (based on 94% sequence homology), bovine (based on 94% sequence homology)

immunocytochemistry: suitable
immunoprecipitation (IP): suitable
western blot: suitable

NP_059043

P21708

wet ice

~44/42 kDa observed. 41.26/36.30 kDa (human MAPK1 isoform 1/2), 41.14 kDa (rat MAPK1), 41.14 kDa (mouse MAPK1), 43.00/38.14 kDa (human MAPK3 isoform 1/2), 42.95/45.64 kDa (rat MAPK3 isoform 1/2), 42.93 kDa (mouse MAPK3) calculated (Met1 removed). Target sequence is not present in human MAPK3 spliced isoform 3 (ERK1b).

Stable for 1 year at 2-8°C from date of receipt.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

12 - Non Combustible Liquids

WGK 1